From a chance meeting in 2016 to building a multi-brand aesthetic empire, 1 Doc International’s rapid rise has redefined non-invasive dermacare—but hyper-growth driven by high profit margins has culminated in a scrapped Main Market IPO and a wave of customer pushback over high-pressure sales tactics.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.